Dr. Kollins brings decades of experience
driving novel approaches to psychopharmacology and ADHD
treatment
Akili, Inc., a leading commercial digital medicine company,
today announced the appointment of Scott Kollins, Ph.D., as chief
medical officer, effective December 1, 2022. Dr. Kollins will
report to Akili’s chief operating officer and join the company’s
executive team.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221201005180/en/
Scott Kollins, Ph.D., Chief Medical
Officer at Akili (Photo: Business Wire)
“Dr. Kollins is one of the nation’s most respected key opinion
leaders in ADHD,” said Matt Franklin, president and COO of Akili.
“His ADHD expertise combined with his experience in innovative
approaches to clinical evidence generation will help guide our
growth and our work to advance new treatments for cognitive
impairments across indications, starting with EndeavorRx® in
ADHD.”
"We have treated ADHD in the U.S. in virtually the same way for
more than 50 years; providers and patients need new options,” said
Dr. Kollins. “Akili is in a unique position to challenge the status
quo and change the treatment paradigm with unique digital medicine
to improve patient care. I have seen firsthand the important role
that EndeavorRx can play in the treatment of children with ADHD,
and I am thrilled to work alongside the talented team at Akili to
help these children and build toward the future of helping tens of
millions of patients living with cognitive health issues.”
Dr. Kollins spent more than 20 years on the faculty in the
Department of Psychiatry and Behavioral Sciences at the Duke
University School of Medicine, where he maintains an adjunct
faculty appointment. He was also the co-lead for the Digital Health
Solutions Initiative at the Duke Clinical Research Institute
(DCRI). In this role, Dr. Kollins worked with more than a dozen
digital health and digital therapeutic companies to develop
clinical studies and provide scientific and regulatory guidance.
Dr. Kollins was most recently the chief medical officer for
Holmusk, the world’s leading real-world evidence company focused on
behavioral health.
Dr. Kollins’ research has spanned a number of areas, including
human psychopharmacology, ADHD across the lifespan, nicotine and
other substance use disorders, and clinical trials. He has
published nearly 200 scientific papers in peer-reviewed journals.
Over the past 20 years, his research was supported by seven
different federal agencies, including the NICHD, NIDA, NIMH, NIEHS,
NINDS, FDA, and EPA. Dr. Kollins has been ranked among the Top 100
Psychiatry faculty members in the U.S. with respect to NIH funding
and also served as principal investigator on more than 50
industry-funded clinical trials, including Akili’s STARS-ADHD trial
published in The Lancet Digital Health. Dr. Kollins is an elected
member of the College on Problems of Drug Dependence and a fellow
of both the American College of Neuropsychopharmacology and the
American Psychological Association Division 28 (Psychopharmacology
and Substance Abuse). He has served as a reviewer for a wide range
of US-based and international granting agencies. Dr. Kollins is a
former associate editor for the Journal of Attention Disorders, is
the ADHD section editor for the Journal of Child Psychiatry &
Psychology and has reviewed for more than 50 different
peer-reviewed journals. He is also a licensed clinical psychologist
in the state of North Carolina.
Dr. Kollins received his undergraduate degree in psychology from
Duke University in 1992 and earned his Master’s and Doctorate
degrees in Clinical Psychology from Auburn University in 1995 and
1997, respectively. He completed his clinical internship at the
University of Mississippi Medical Center, where he served as chief
intern. Following internship, Kollins joined the faculty of the
Department of Psychology at Western Michigan University for three
years, before joining the Duke faculty in 2000.
EndeavorRx Indication and Overview
EndeavorRx is the first-and-only FDA-authorized treatment
delivered through a video game experience. EndeavorRx is indicated
to improve attention function as measured by computer-based testing
in children ages 8 to 12 years old with primarily inattentive or
combined-type ADHD, who have a demonstrated attention issue.
Patients who engage with EndeavorRx demonstrate improvements in a
digitally assessed measure Test of Variables of Attention (TOVA®)
of sustained and selective attention and may not display benefits
in typical behavioral symptoms, such as hyperactivity. EndeavorRx
should be considered for use as part of a therapeutic program that
may include clinician-directed therapy, medication, and/or
educational programs, which further address symptoms of the
disorder. EndeavorRx is available by prescription only. It is not
intended to be used as a stand-alone therapeutic and is not a
substitution for a child’s medication. The most common side effect
observed in children in EndeavorRx’s clinical trials was a feeling
of frustration, as the game can be quite challenging at times. No
serious adverse events were associated with its use. EndeavorRx is
recommended to be used for approximately 25 minutes a day, 5 days a
week, over initially at least 4 consecutive weeks, or as
recommended by your child’s health care provider. To learn more
about EndeavorRx, please visit EndeavorRx.com.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Akili’s approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine – medicine that is validated through
clinical trials like a drug or medical device, but experienced like
entertainment. Akili’s platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili’s belief that
effective medicine can also be fun and engaging, Akili’s products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the development and
commercialization of EndeavorRx and other digital medicine and
other risks identified in our filings made with the Securities and
Exchange Commission (SEC). We caution you not to place undue
reliance on any forward-looking statements, which speak only as of
the date hereof and should not be relied upon as representing the
company’s views as of any subsequent date. We disclaim any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221201005180/en/
Julie DiCarlo SVP, Communications julie@akiliinteractive.com
Akili (NASDAQ:AKLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akili (NASDAQ:AKLI)
Historical Stock Chart
From Apr 2023 to Apr 2024